A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00282347
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUGRituximab was provided as a sterile solution for injection.
- Placebo — DRUGPlacebo was provided as a sterile solution for injection.
- Mycophenolate mofetil — DRUG
- Methylprednisolone — DRUG
- Diphenhydramine — DRUG
- Acetaminophen — DRUG
- Prednisone — DRUG
Study Details
This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in subjects diagnosed with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis.
Key Dates
- Start date
- Jan 31, 2006
- Status verified
- Jan 2015
- Primary completion
- Jan 31, 2009
- Completion
- Jan 31, 2013
Study Design
- Enrollment
- 144 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: RituximabParticipants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
- Placebo Comparator: PlaceboParticipants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
Primary Outcome Measure
Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 [ Time Frame: Week 52 ]
Related Studies
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)Recruiting · The Rogosin Institute · New York, New York
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPHASE2 · Recruiting · Hoffmann-La Roche · Loma Linda, California
- VIBRANT: VIB4920 for Active Lupus NephritisPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPHASE2 · Recruiting · Novartis Pharmaceuticals · Phoenix, Arizona